Collaboration and License Agreements - Pfizer Collaboration and License Agreement (Details)		1 Months Ended	6 Months Ended	12 Months Ended
	Dec. 26, 2020 USD ($) milestone	Dec. 31, 2020 USD ($)	Sep. 30, 2022 USD ($)	Dec. 31, 2022 USD ($)	Dec. 31, 2021 USD ($)	Mar. 31, 2022 USD ($)	Jul. 31, 2021 USD ($)
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Proceeds received from license agreement milestone	$ 146,400,000		$ 0
Amounts due to Pfizer			38,939,000			$ 32,563,000
Pfizer
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of revenue recognized	100.00%
Upfront payment received		$ 650,000,000
Proceeds received from license agreement milestone	$ 150,000,000		100,000,000
Maximum payment from milestones achieved	$ 3,800,000,000
Number of regulatory milestones | milestone	2
Maximum payment from regulatory milestones achieved	$ 100,000,000						$ 100,000,000
Maximum aggregate payment from milestones achieved	200,000,000
Maximum payment from sales-related milestones achieved	$ 3,500,000,000
Costs covered by company					$ 100,000,000
Repayment period	2 years
Reduction in cost share advance from implied financing costs	$ 3,600,000
Deferred revenue, recognition period	6 years
Amounts due to Pfizer			38,900,000			32,600,000
Amounts due to collaboration partner, share of profits			$ 22,400,000			$ 14,100,000
Percentage of revenue recognized by counterparty			50.00%			50.00%
Amounts due to collaboration partner, reimbursement of allowable expenses			$ 16,500,000			$ 18,500,000
Reimbursement of allowable expenses (as a percent)			50.00%			50.00%
Reimbursement of total expenses (as a percent)			100.00%
Pfizer | Forecast
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Costs covered by company				$ 50,000,000